Could a shot retrain the immune system to stop type 1 diabetes?
NCT ID NCT03624062
First seen Feb 15, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This early-stage trial tested a new immunotherapy (IBC with MAS-1) in 21 adults recently diagnosed with type 1 diabetes. The goal was to see if the treatment is safe and can retrain the immune system to stop attacking the pancreas, potentially preserving the body's ability to make insulin. Participants received either the study drug or a placebo, and researchers monitored side effects and immune system changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Colorado, Denver
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.